Catalent Pharma Solutions acquires cell and gene therapy CDMO MaSTherCell

Drug manufacturer Catalent Pharma Solutions has wrapped up its previously announced $315 million acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization (cell and gene therapy CDMO).

The acquisition, which was announced earlier this month, is said to position Catalent as a major technology, development, and manufacturing partner for innovators of advanced biotherapeutics.

Catalent claims that it is well poised to lead the industry with its cell and gene therapy platforms following the addition of MaSTherCell’s portfolio of capabilities, technologies, and related analytical services that span autologous and allogeneic cell therapies.

The acquisition adds MaSTherCell’s 25,000sft clinical services facility in Gosselies, Belgium, and its 32,000sft facility in Houston, Texas to Catalent’s network. The Houston facility of MaSTherCell, which will focus on development-scale projects is slated to open later this quarter.

Catalent said that it will make use of its resources and expertise in build-outs, scale-ups, and commercial manufacturing to support the expansion that is in progress of a 60,000sft commercial-scale cell therapy production and fill-finish facility to be located near the existing MaSTherCell’s clinical services facility in Gosselies, which is due to open in the fall of next year.

Catalent Pharma Solutions acquires cell and gene therapy CDMO MaSTherCell. Photo courtesy of MaSTherCell.